How does Mounjaro work for weight loss? Tirzepatide explained

Mounjaro is the brand name for tirzepatide, a prescription medicine given as a once-weekly injection. In the UK it is authorised for weight management in adults alongside a reduced-calorie diet and increased physical activity. It is also used for type 2 diabetes. The weight-management indication is not a licence to use it as a cosmetic shortcut or without medical supervision.

The short version of how it works: tirzepatide changes signals involved in appetite, fullness and blood-sugar regulation. It does not "burn fat" directly.

One medicine, two hormone targets

After food, the gut releases hormones that help coordinate digestion, appetite and blood glucose. Tirzepatide activates receptors for two of them: GIP and GLP-1. This is why it is described as a dual GIP/GLP-1 receptor agonist.

The result is not simply that food moves more slowly through the stomach. Tirzepatide can increase feelings of fullness, reduce hunger and food cravings, and reduce how much a person eats. It also supports glucose-dependent insulin release and affects other aspects of blood-sugar regulation. Delayed stomach emptying is part of its action, particularly around treatment initiation, but appetite and energy intake are central to its weight effect. The UK product information describes these appetite and energy-intake effects.

That distinction matters. Mounjaro is not a substitute for nutrition, movement, sleep or medical care. It can make eating less feel more manageable for some people; it does not make every food choice irrelevant, and it does not guarantee a particular number on the scales.

What did the weight-loss trials find?

In SURMOUNT-1, 2,539 adults with obesity, or overweight plus a weight-related condition, were assigned to weekly tirzepatide or placebo for 72 weeks. Participants did not have type 2 diabetes, and the programme included lifestyle support. Average weight change at week 72 was −15.0% with 5 mg, −19.5% with 10 mg and −20.9% with 15 mg. The placebo group averaged −3.1%. These are trial averages using the treatment-regimen analysis, which includes participants regardless of whether they stopped treatment. The published trial report sets out the study design and results.

For scale, a 20% change in someone who starts at 100 kg is 20 kg. That arithmetic can help make percentages tangible; it is not a forecast for an individual. Starting weight, dose tolerated, treatment duration, other health conditions, adherence and side effects all matter. Some people lose less; some lose more; some stop treatment.

The evidence also differs for people with type 2 diabetes. In the separate 72-week SURMOUNT-2 study, the UK label's efficacy-estimand analysis, which estimates the result if participants had stayed on their assigned treatment, reported average weight changes of −13.4% with 10 mg and −15.7% with 15 mg, compared with −3.3% with placebo. Those figures are not directly comparable with SURMOUNT-1's treatment-regimen estimates above: the trial populations and statistical questions differ. The current UK product information summarises both studies.

Is the benefit only about weight?

The trials recorded changes in waist circumference, blood pressure and some blood-fat measures as well as weight. In a body-composition sub-study, most of the weight lost was fat mass, including visceral fat, but participants also lost some lean mass. This is one reason a good treatment plan should discuss strength, nutrition and preserving function, rather than focusing on the scale alone.

What the trial number cannot tell you

A clinical-trial average is not a promise, a minimum result or a deadline. Trial participants were selected, monitored and supported; their experience may not mirror every person using the medicine in routine care. A high dose is not automatically the right dose, and a slower rate of loss does not mean treatment has failed.

Ask the prescriber what a meaningful result would look like for your health, how progress will be reviewed, what to do if side effects interfere with eating or drinking, and how treatment would be managed if it needs to stop. Mounjaro is one tool in a longer-term plan, not a 72-week guarantee.